Default company panoramic image
Logo

ITI Technology

Providing lipid-based nanoparticles to localize cancer immunotherapy and to induce immunological tolerance of protein-based biotherapeutics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Amherst, NY, USA
  • Currency USD

Company Summary

Company focused on the treatment of diseases within the (1) oncology, (2) autoimmune, (3) hemophilia, and (4) lysosomal storage spaces. Protein-based drugs hold promise for treating many diseases, however the body’s immune system often pegs the proteins as "foreign" and attacks them. To address this problem, ITI uses lipid-based nanoparticles that “teach” the immune system to tolerate protein therapeutics, avoiding treatment complications.

Team

  • Default avatar
    Dennis Goupil
    CEO

    Proven leader with 25 years experience as Chief Technical Officer / Vice-President / Director of Research & Development in medical devices and generic drugs. He has held senior management positions with Boston Scientific, Davis & Geck division of American Cyanamid, Datascope, Pharmacia Ophthalmics, Minrad Inc, and BioCure.

  • Default avatar
    Dr. Richard Bankert
    CSO

    Internationally recognized expert whose research defines the molecular and cellular events that shape the function of human tumor associated lymphocytes. This research has been used to develop ITI cancer therapy.

  • Default avatar
    Dr. Steven Bernstein
    Scientific Advisor

    Professor of Medicine and Co-Director of the
    Lymphoma Biology Program at the James P. Wilmot Cancer Center, University of Rochester Medical Center. He earned a medical degree from the New York University School of Medicine.

  • Default avatar
    Anas Fathallah
    Technical Program Manager

    Graduate research assistant and PhD candidate in the Department of Pharmaceutical Sciences, University at Buffalo. Works in the lab of Dr. Sathy Balu-Iyer, inventor of the technology.

  • Default avatar
    Dr. Sathy Balu-Iyer
    Scientific Advisor

    Professor of Pharmaceutical Sciences at SUNY Buffalo the inventor of ITI Technology nanoparticles. Dr. Balu-Iyer has been awarded the Innovation in Biotechnology Award (American Assoc. of Pharmaceutical Scientists, May 2012) and the Inventor of the Year Award (Niagara Frontier IP Law Association, 2011)